Avatrombopag for aplastic anemia that didn't respond to treatment
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a new pill called avatrombopag to see if it can help increase the number of platelets (cells that help blood clot) in adults with aplastic anemia who have not improved with standard treatments. It may be an option if your disease is hard to treat.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have aplastic anemia, confirmed by your doctor.
- You have not responded to, or your disease has come back after, at least one course of immunosuppressive therapy (like ATG).
- Your platelet count is 30,000 or lower.
- You are able to be up and about, even if you need some help (performance status 0-2).
- If you are a woman who can become pregnant, you must agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for children and teenagers (ages 6 to 17) with aplastic anemia who are starting eltrombopag (Revolade) for the first time, taken together with ATG (a medicine that helps the immune system). The study will monitor how well the treatment works and how safe it is.
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
This study tests an experimental treatment made from special immune cells designed to help your body fight aplastic anemia. It may be an option if you still need blood transfusions despite standard treatments.
This trial studies whether avatrombopag can help your platelet count recover after a bone marrow transplant from an unrelated donor (UCBT) in certain bone marrow failure diseases. If platelets recover better, it may reduce risks related to low platelets after transplant.
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.